Cargando…

Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study

Afatinib, an irreversible ErbB-family blocker, could improve the survival of advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer patients (NSCLCm+). This phase II trial (NCT04201756) aimed to assess the feasibility of neoadjuvant Afatinib treatment for stage III NSCLCm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bian, Dongliang, Sun, Liangdong, Hu, Junjie, Duan, Liang, Xia, Haoran, Zhu, Xinsheng, Sun, Fenghuan, Zhang, Lele, Yu, Huansha, Xiong, Yicheng, Huang, Zhida, Zhao, Deping, Song, Nan, Yang, Jie, Bao, Xiao, Wu, Wei, Huang, Jie, He, Wenxin, Zhu, Yuming, Jiang, Gening, Zhang, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400609/ https://www.ncbi.nlm.nih.gov/pubmed/37537219 http://dx.doi.org/10.1038/s41467-023-40349-z

Ejemplares similares

The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center
por: Xiong, Yicheng, et al.
Publicado: (2023)

Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial
por: Zhu, Xinsheng, et al.
Publicado: (2022)

Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing
por: Hu, Junjie, et al.
Publicado: (2023)

The efficacy and safety of wedge resection for peripheral stage IA lung adenocarcinoma: a real-world study based on a single center
por: Bian, Dongliang, et al.
Publicado: (2023)

Identification of an Individualized Metabolism Prognostic Signature and Related Therapy Regimens in Early Stage Lung Adenocarcinoma
por: Hu, Junjie, et al.
Publicado: (2021)

Neoadjuvant immunotherapy combined with chemotherapy for local advanced non-small cell lung cancer: a case report
por: Yang, Jie, et al.
Publicado: (2021)

Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer
por: Dai, Jie, et al.
Publicado: (2022)

Comparative profiling of single-cell transcriptome reveals heterogeneity of tumor microenvironment between solid and acinar lung adenocarcinoma
por: Li, Dianke, et al.
Publicado: (2022)

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022)

Case Report: Afatinib Sensitivity in Rare EGFR E746_L747delinsIP Mutated LUAD With Peritoneal Metastases
por: Zhang, Lili, et al.
Publicado: (2022)

Comparison of perioperative outcomes among non-small cell lung cancer patients with neoadjuvant immune checkpoint inhibitor plus chemotherapy, EGFR-TKI, and chemotherapy alone: a real-world evidence study
por: Zhao, Deping, et al.
Publicado: (2022)

Single-cell transcriptome and antigen-immunoglobin analysis reveals the diversity of B cells in non-small cell lung cancer
por: Chen, Jian, et al.
Publicado: (2020)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Differentiation-related genes in tumor-associated macrophages as potential prognostic biomarkers in non-small cell lung cancer
por: Li, Zhaoxun, et al.
Publicado: (2023)

Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
por: Chen, Yen-Ju, et al.
Publicado: (2019)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR ‐mutated NSCLC treated with afatinib
por: Wu, Chen‐Te, et al.
Publicado: (2023)

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials
por: Sun, Li, et al.
Publicado: (2021)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019)

Simultaneous Inhibition of EGFR and HER2 via Afatinib Augments the Radiosensitivity of Nasopharyngeal Carcinoma Cells
por: Huang, Fangling, et al.
Publicado: (2019)

Hybrid uniportal robotic-assisted thoracoscopic surgery using video-assisted thoracoscopic surgery staplers: technical aspects and results
por: E, Haoran, et al.
Publicado: (2022)

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
por: Harvey, R Donald, et al.
Publicado: (2020)

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S
por: Wei, Yang, et al.
Publicado: (2021)

Afatinib 30 mg in the treatment of common and uncommon EGFR-mutated advanced lung adenocarcinomas: a retrospective, single-center, longitudinal study
por: Qian, Jie, et al.
Publicado: (2022)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

Development and validation of nomogram prognostic model for early-stage T1-2N0M0 small cell lung cancer: A population-based analysis
por: Ge, Tao, et al.
Publicado: (2022)

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
por: Ribeiro Gomes, Jéssica, et al.
Publicado: (2015)

Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase
por: Yu, Cheng-Han, et al.
Publicado: (2018)

Comprehensive study of neoadjuvant targeted therapy for resectable non-small cell lung cancer
por: Bao, Yi, et al.
Publicado: (2021)

An individualized immune prognostic signature in lung adenocarcinoma
por: Sun, Liangdong, et al.
Publicado: (2020)

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

Author Correction: Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
por: Chen, Yen-Ju, et al.
Publicado: (2021)

EGFR mutations are significantly associated with visceral pleural invasion development in non-small-cell lung cancer patients
por: Shi, Jinghan, et al.
Publicado: (2019)

Comprehensive genomic profiling of combined small cell lung cancer
por: Zhang, Jing, et al.
Publicado: (2021)

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
por: Huang, Chun-Yao, et al.
Publicado: (2023)

Simultaneous bilateral thoracoscopic lobectomy for synchronous bilateral multiple primary lung cancer—single center experience
por: Zheng, Hui, et al.
Publicado: (2021)

Single‐Cell Transcriptome Identifies Drug‐Resistance Signature and Immunosuppressive Microenvironment in Metastatic Small Cell Lung Cancer
por: Zhang, Jing, et al.
Publicado: (2022)

Prognostic factors and role of postoperative radiotherapy in surgically resected thymomas
por: Yang, Fujun, et al.
Publicado: (2023)

Correlation between tumor location and survival in stage I lung adenocarcinoma and squamous cell carcinoma: a SEER-based study
por: Hu, Junjie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c00vn7jpa9faciaufpabpatjmb